Aurobindo Pharma receives final approval for Didanosine Delayed Release Capsules

Aurobindo Pharma Limited is pleased to announce that the company has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Didanosine Delayed Release (Enteric-Coated) Capsules 125mg, 200mg, 250mg and 400mg

Didanosine Delayed Release Capsules is the generic version of Bristol Myer Squibb's Videx® EC (Didanosine) Delayed-release Capsules, 125mg, 200mg, 250mg and 400mg and is indicated for the treatment of HIV-1 infections in adults.

This is Aurobindo's 78th ANDA approval from the USFDA.

About Aurobindo Pharma Limited:

Aurobindo Pharma Limited (www.aurobindo.com), headquartered at Hyderabad, India, manufactures generic pharmaceuticals and active pharmaceutical ingredients. The company's manufacturing facilities are approved by several leading regulatory agencies like US FDA, UK MHRA, WHO, Health Canada, MCC South Africa, ANVISA Brazil. The company's robust product portfolio is spread over 6 major therapeutic/product areas encompassing Antibiotics, Anti-Retrovirals, CVS, CNS, Gastroenterologicals, and Anti-Allergics, supported by an outstanding R&D set-up. The Company is marketing these products globally, in over 100 countries..

For further information, please contact:
Investor Relations
Aurobindo Pharma Limited
Reg Off: Plot No. 2, Maitrivihar, Ameerpeth, Hyderabad
Phone: 040-66725000 / 66725401
Email: ir@aurobindo.com